Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
Stephen Williams, MD, MBA, MS, FACS, FACHE
Advertisement
Stephen Williams, MD, MBA, MS, FACS, FACHE, is a professor and Chief of the Division of Urology, Department of Surgery at the University of Texas Medical Branch in Galveston, TX.
Articles by Stephen Williams, MD, MBA, MS, FACS, FACHE
Stephen Williams, MD, MBA, MS, FACS, FACHE, discusses new and exciting developments in the bladder cancer treatment landscape.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
